114 related articles for article (PubMed ID: 32769503)
1. Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors.
Vistisen ST; Bodilsen J; Scheeren TWL; Simonsen U
Eur J Anaesthesiol; 2020 Sep; 37(9):739-742. PubMed ID: 32769503
[No Abstract] [Full Text] [Related]
2. RAAS blockers in hypertension posing a higher risk toward the COVID-19.
Singh Y; Gupta G; Satija S; Negi P; Chellappan DK; Dua K
Dermatol Ther; 2020 Jul; 33(4):e13501. PubMed ID: 32359088
[No Abstract] [Full Text] [Related]
3. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
Guo X; Zhu Y; Hong Y
Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
[No Abstract] [Full Text] [Related]
4. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.
Meng J; Xiao G; Zhang J; He X; Ou M; Bi J; Yang R; Di W; Wang Z; Li Z; Gao H; Liu L; Zhang G
Emerg Microbes Infect; 2020 Dec; 9(1):757-760. PubMed ID: 32228222
[TBL] [Abstract][Full Text] [Related]
5. [Renin-angiotensin system blockers and COVID-19 infection].
Ruilope LM; Garcia Donaire JA; de la Sierra A
Hipertens Riesgo Vasc; 2020; 37(3):99-100. PubMed ID: 32448641
[No Abstract] [Full Text] [Related]
6. Renin-angiotensin-aldosterone system inhibitors and COVID-19.
Quinn KL; Fralick M; Zipursky JS; Stall NM
CMAJ; 2020 May; 192(20):E553-E554. PubMed ID: 32332039
[No Abstract] [Full Text] [Related]
7. Relationship between angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and SARS-CoV-2 infection: where are we?
Infusino F; Cimino S; Lombardi M; Mancone M; Cavarretta E; Frati G; Pugliese F; Fedele F; Biondi Zoccai G
Minerva Cardioangiol; 2020 Aug; 68(4):339-346. PubMed ID: 32472989
[TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.
Lévy BI; Fauvel JP;
Arch Cardiovasc Dis; 2020; 113(8-9):572-578. PubMed ID: 32863157
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications.
Hrenak J; Zorad S; Simko F
Gen Physiol Biophys; 2020 May; 39(3):203-204. PubMed ID: 32525813
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399
[No Abstract] [Full Text] [Related]
11. ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations.
Snyder EM; Johnson BD
Pharmacogenomics; 2020 Jul; 21(10):695-703. PubMed ID: 32501190
[TBL] [Abstract][Full Text] [Related]
12. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
[No Abstract] [Full Text] [Related]
13. [Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].
Mareev YV; Mareev VY
Kardiologiia; 2020 Apr; 60(4):4-9. PubMed ID: 32394850
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the renin angiotensin system: proven benefits, unproven safety.
Parfrey PS
Ann Intern Med; 2008 Jan; 148(1):76-7. PubMed ID: 17984483
[No Abstract] [Full Text] [Related]
15. [Dual blockade of the renin-angiotensin system in hypertensive treatment: no].
van der Giet M
Dtsch Med Wochenschr; 2012 Nov; 137(48):2499. PubMed ID: 23168984
[No Abstract] [Full Text] [Related]
16. [COVID-19 and its relationship with hypertension and cardiovascular disease].
Salazar M; Barochiner J; Espeche W; Ennis I
Hipertens Riesgo Vasc; 2020; 37(4):176-180. PubMed ID: 32591283
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin system inhibitors in kidney transplantation: a benefit-risk assessment.
Ponticelli C; Cucchiari D
J Nephrol; 2017 Apr; 30(2):155-157. PubMed ID: 28211033
[No Abstract] [Full Text] [Related]
18. Plasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System.
Kintscher U; Slagman A; Domenig O; Röhle R; Konietschke F; Poglitsch M; Möckel M
Hypertension; 2020 Nov; 76(5):e34-e36. PubMed ID: 32851897
[No Abstract] [Full Text] [Related]
19. Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.
Chen C; Wang F; Chen P; Jiang J; Cui G; Zhou N; Moroni F; Moslehi JJ; Ammirati E; Wang DW
J Am Heart Assoc; 2020 Nov; 9(21):e017736. PubMed ID: 32807002
[TBL] [Abstract][Full Text] [Related]
20. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
